MedTrace Logo

Subconjunctival Bevacizumab Effect on Bleb Vascularity

NCT00854529 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2009-03-03

No results posted yet for this study

Summary

Trabeculectomy is an ocular surgery intended to reduce intra-ocular pressure the surgery creates a sub-conjunctival filtering bleb which filters aqueous humor fluid out.

A rather common adverse event of the surgery is increasing vascularity of the conjunctiva overlying the bleb. This leads to adherence of the conjunctiva to the sclera and fibrosis and finally failure of the bleb (and of the surgery) this study intends to demonstrate that post operative subconjunctival bevacizumab injection will reduce incidence of bleb vascularity and ultimately, bleb failure.

Conditions

  • Bleb Vascularity
  • Bleb Fibrosis
  • Trabeculectomy Failure

Interventions

DRUG

Bevacizumab

sub-conjunctival injection of 1.25mg Bevacizumab

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Principal Investigators

  • moshe lusky, MD · Rabin Medical Center

  • omer Y bialer, MD · rabin medial center

  • anat robinson, MD · Rabin Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-04-30
Completion
2011-10-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00854529 on ClinicalTrials.gov